These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

396 related articles for article (PubMed ID: 23239905)

  • 21. Rifaximin for treatment of hepatic encephalopathy.
    Maclayton DO; Eaton-Maxwell A
    Ann Pharmacother; 2009 Jan; 43(1):77-84. PubMed ID: 19092143
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Modulation of the metabiome by rifaximin in patients with cirrhosis and minimal hepatic encephalopathy.
    Bajaj JS; Heuman DM; Sanyal AJ; Hylemon PB; Sterling RK; Stravitz RT; Fuchs M; Ridlon JM; Daita K; Monteith P; Noble NA; White MB; Fisher A; Sikaroodi M; Rangwala H; Gillevet PM
    PLoS One; 2013; 8(4):e60042. PubMed ID: 23565181
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Review article: bacterial flora and pathogenesis in hepatic encephalopathy.
    Williams R
    Aliment Pharmacol Ther; 2007 Feb; 25 Suppl 1():17-22. PubMed ID: 17295848
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Gut : liver : brain axis: the microbial challenge in the hepatic encephalopathy.
    Mancini A; Campagna F; Amodio P; Tuohy KM
    Food Funct; 2018 Mar; 9(3):1373-1388. PubMed ID: 29485654
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Rifaximin: a review of its use in reducing recurrence of overt hepatic encephalopathy episodes.
    Scott LJ
    Drugs; 2014 Dec; 74(18):2153-60. PubMed ID: 25352391
    [TBL] [Abstract][Full Text] [Related]  

  • 26. RiMINI - the influence of rifaximin on minimal hepatic encephalopathy (MHE) and on the intestinal microbiome in patients with liver cirrhosis: study protocol for a randomized controlled trial.
    Schulz C; Schütte K; Kropf S; Schmitt FC; Vasapolli R; Kliegis LM; Riegger A; Malfertheiner P
    Trials; 2016 Feb; 17(1):111. PubMed ID: 26926775
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Updates on the pathophysiology and therapeutic targets for hepatic encephalopathy.
    Alsahhar JS; Rahimi RS
    Curr Opin Gastroenterol; 2019 May; 35(3):145-154. PubMed ID: 30893082
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Prevention of hepatic encephalopathy].
    Morillas RM; Sala M; Planas R
    Med Clin (Barc); 2014 Jun; 142(11):512-4. PubMed ID: 24480288
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Gut flora and hepatic encephalopathy in patients with cirrhosis.
    Riordan SM; Williams R
    N Engl J Med; 2010 Mar; 362(12):1140-2. PubMed ID: 20335591
    [No Abstract]   [Full Text] [Related]  

  • 30. Distinct responsiveness to rifaximin in patients with hepatic encephalopathy depends on functional gut microbial species.
    Yukawa-Muto Y; Kamiya T; Fujii H; Mori H; Toyoda A; Sato I; Konishi Y; Hirayama A; Hara E; Fukuda S; Kawada N; Ohtani N
    Hepatol Commun; 2022 Aug; 6(8):2090-2104. PubMed ID: 35429147
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Salivary microbiota reflects changes in gut microbiota in cirrhosis with hepatic encephalopathy.
    Bajaj JS; Betrapally NS; Hylemon PB; Heuman DM; Daita K; White MB; Unser A; Thacker LR; Sanyal AJ; Kang DJ; Sikaroodi M; Gillevet PM
    Hepatology; 2015 Oct; 62(4):1260-71. PubMed ID: 25820757
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Nontraditional Treatment of Hepatic Encephalopathy.
    Singh J; Ibrahim B; Han SH
    Clin Liver Dis; 2024 May; 28(2):297-315. PubMed ID: 38548441
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparison of once a day rifaximin to twice a day dosage in the prevention of recurrence of hepatic encephalopathy in patients with chronic liver disease.
    Khokhar N; Qureshi MO; Ahmad S; Ahmad A; Khan HH; Shafqat F; Salih M
    J Gastroenterol Hepatol; 2015 Sep; 30(9):1420-2. PubMed ID: 25867912
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Rifaximin in the treatment of chronic hepatic encephalopathy.
    Puxeddu A; Quartini M; Massimetti A; Ferrieri A
    Curr Med Res Opin; 1995; 13(5):274-81. PubMed ID: 7555036
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Update on management of patients with overt hepatic encephalopathy.
    Chacko KR; Sigal SH
    Hosp Pract (1995); 2013 Aug; 41(3):48-59. PubMed ID: 23948621
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Prevention and treatment of hepatic encephalopathy].
    Sivolap YP
    Zh Nevrol Psikhiatr Im S S Korsakova; 2017; 117(10):144-147. PubMed ID: 29171503
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Lactulose, rifaximin or branched chain amino acids for hepatic encephalopathy: what is the evidence?
    Gluud LL; Dam G; Borre M; Les I; Cordoba J; Marchesini G; Aagaard NK; Vilstrup H
    Metab Brain Dis; 2013 Jun; 28(2):221-5. PubMed ID: 23275147
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Inflammation and hepatic encephalopathy.
    Coltart I; Tranah TH; Shawcross DL
    Arch Biochem Biophys; 2013 Aug; 536(2):189-96. PubMed ID: 23583306
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Introduction: understanding mechanisms of the actions of rifaximin in selected gastrointestinal diseases.
    DuPont HL
    Aliment Pharmacol Ther; 2016 Jan; 43 Suppl 1():1-2. PubMed ID: 26618920
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Mechanisms, diagnosis and management of hepatic encephalopathy.
    Prakash R; Mullen KD
    Nat Rev Gastroenterol Hepatol; 2010 Sep; 7(9):515-25. PubMed ID: 20703237
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.